Teams export Cortellis records, then check them by hand against company pipelines and press releases. Sleuth checks each program’s status and phase at its source, and builds the analysis your question needs.
Every Sleuth plan comes with the drugs, trials, companies, and deals you’d look up in Cortellis. Sleuth then builds the analysis for your question.
Landscapes, partner and asset searches, and deal comps, built on records checked at the source.
Your regulatory, CMC, or drug-safety team works in its regulatory products every day.
A database subscription
$20K+ a year
The database alone. The analysis is still on you.
Sleuth
From $249 a month
Everything your database has, plus 3,000 credits a month.
Sleuth
Cortellis
Sleuth
Included in every plan: drugs, trials, companies, and deals in one knowledge base. Browsing is free and doesn’t use credits.
Cortellis
Sold product by product: pipeline, deals, trials, and regulatory data are each a separate product.
Sleuth
The standard fields, plus any column you ask for. Ask “who holds the rights outside the US?” and Sleuth adds it as a column, filled in for every program.
Cortellis
Limited to its “more than 20 granular filters.” For anything else, you export the records and work it out by hand.
Sleuth
Click any value to see the filing, registry entry, or broker note behind it, with its date, a confidence score, and whether it’s sourced, inferred, or unknown. Sleuth flags the few cells worth checking.
Cortellis
You check the records yourself, against company pipelines and press releases. Its AI assistant answers from the same records.
Sleuth
Tens of thousands of updates a day, each checked at its source: company pipelines, filings, 20 trial registries, and news. A stopped program shows as stopped, with the reason when there’s a public one.
Cortellis
Buyers tell us a program can stay listed as active after the company drops it, and the reason it stopped is rarely recorded.
Sleuth
Taken from each program’s own registry entry or filing, with the source beside it.
Cortellis
An early program can stay listed as preclinical after it has started Phase 2.
Sleuth
About 22,000 Chinese programs, read in Chinese from China’s registries, filings, and patents.
Cortellis
Chinese programs often show up late, once an English source reports them.
Sleuth
Turn on monitoring, and the dataset updates as trials, filings, and deals come in, with a change log and earlier versions kept.
Cortellis
Alerts on the records you follow, but a landscape you exported doesn’t update. You rebuild it.
Sleuth
Builds the analysis for your question from the knowledge base and the documents behind it, in Studio or in Claude, ChatGPT, and Copilot.
Cortellis
Its AI assistant answers from the same fixed fields as the database.
Sleuth
From 35+ providers, in every plan. Read any report in full, and search it next to the knowledge base.
Cortellis
Not part of Cortellis.
Cortellis users tell us its records lag: stopped programs still listed as active, Phase 2 programs still called preclinical. Sleuth checks company pipelines, filings, 20 trial registries, and news, and makes tens of thousands of updates a day.
Cortellis sells itself on early pipeline coverage, yet it often lists Chinese and early programs late. Sleuth reads patents and China’s registries and filings, so you see a program when it’s first disclosed.
~22,000
Chinese programs, read in Chinese
~60%
of the 150K+ drugs in the knowledge base are preclinical
300K+
patents, where new programs often show up first
Cortellis sells pipeline, deal, trial, and regulatory data as separate products, joined “with direct links and single sign-on.” In Sleuth, they’re one knowledge base, with sell-side research beside it.
Pipeline and competitors
A separate Cortellis product
Clinical trials
A separate Cortellis product
Deals
A separate Cortellis product
Sell-side research
Not part of Cortellis
Our analysts build each Intel Hub report on a Sleuth dataset, with each program’s status checked at its source.
About 200 clinical degrader programs, with the date and reason for every stop.
Most clinical oligonucleotide programs act outside the liver, but only about 12% reach distant tissue.
628 active programs as of August 2026, and Chinese developers run 323 of them.
Keep Cortellis if your regulatory, CMC, or drug-safety team works in its regulatory products every day. For pipeline, landscape, and BD work, Sleuth replaces it, and builds the analysis on top.
Your regulatory team follows guidance and submission requirements country by country.
Your CMC team checks manufacturing regulations and local practice before each submission.
Your safety team looks for drug and class toxicity across preclinical and clinical data.
For pipeline, landscape, and BD work, yes: competitive landscapes, asset and partner searches, and deal comps. Every plan includes the drugs, trials, companies, and deals you’d look up in Cortellis. Keep Cortellis if your regulatory, CMC, or drug-safety team works in its regulatory products every day.
It checks each program at its source: company pipeline pages and filings, 20 trial registries, and news. When a program drops off a pipeline or its trial ends, Sleuth updates the status and records the reason the company gave. When there’s no stated reason, Sleuth infers one from the last reported data and marks it inferred, with the sources beside it.
Analysis built for your question, a knowledge base of drugs, trials, companies, and deals, and searchable documents, including sell-side research from 35+ providers. Browsing the knowledge base and reading the research are free. You can try all of it free for 14 days.
Yes. In August 2026, Cortellis added agentic workflows to its competitive intelligence product. They answer from the same records as the database. Sleuth builds the analysis for your question from its knowledge base and the documents behind it, with a source on every value.
Yes, about 22,000, read in Chinese from China’s registries, filings, patents, and medical meetings, in the same landscape as every other program.
Yes. Upload your own files in Studio, and Sleuth reads them alongside its knowledge base and documents.